重用甲福明:一种潜在的非标签性指示,用于缺血性中风?
1Department of Biomedical Sciences, University of Illinois at Chicago, College of Medicine Rockford, Rockford, Illinois, USA.
Diabetes, obesity & metabolism
|November 27, 2024
概括
甲胺在治疗缺血性中风方面表现有前途,这是导致死亡的主要原因. 本综述汇集了关于重用甲福明治疗中风的证据,解决了差异,并提供了改善患者结果的解决方案.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 药物重用 药物重用
背景情况:
- 缺血性中风是全球死亡率和长期残疾的主要原因.
- 目前的治疗方法,如组织等离子体激活剂,治疗窗口有限.
- 脑卒中后康复提供了好处,但缺乏迅速性.
研究的目的:
- 审查用于治疗缺血性中风的metformin重定向的潜力.
- 收集和分析临床前和临床试验数据.
- 解决不一致问题,并提出用于中风中甲福明的解决方案.
主要方法:
- 临床前研究的系统审查.
- 对临床试验数据的分析.
- 评估甲胺在中风中的预防和治疗作用.
主要成果:
- 在过去的十年里,对中风进行了广泛的研究.
- 有证据表明,在预防和治疗缺血性中风方面都有潜在的益处.
- 当前数据中的差异需要澄清.
结论:
- 药物重新定位,特别是甲胺,为扩大缺血性中风治疗选择提供了一个有希望的途径.
- 需要进一步的研究来澄清差异,并优化甲胺的应用.
- 甲胺可以为中风管理策略提供一种有价值的补充.
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171